Biomarkers for the detection and prognosis of prostate cancer

Current Urology Reports

Volumn 6, Issue 3, 2005, Pages 171-176

  Hernandez, Javier ^a   Canby Hagino, Edith ^b   Thompson, Ian M ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b NONE

Author keywords

Finasteride; Localize Prostate Cancer; Prostate Cancer; Radiation Therapy Oncology Group; Radical Prostatectomy

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ALPHA-METHYLACYL-COA RACEMASE; ISOMERASE; ISOPROTEIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

BLOOD; GENETIC MARKER; GENETICS; HUMAN; MALE; METABOLISM; METHODOLOGY; PROGNOSIS; PROSTATE TUMOR; PROTEOMICS; REVIEW; URINE;

GENETIC MARKERS; HUMANS; MALE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; PROTEOMICS; RACEMASES AND EPIMERASES; TUMOR MARKERS, BIOLOGICAL;

EID: 26944503955     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-005-0004-7     Document Type: Article

References (86)

1. Ablin R, Bronson P, Soanes W, Witebsky E: Tissue- and speciesspecific antigens of normal human prostatic tissue. J Immunol 1970, 104:1329 -1339.
2. Ablin R, Soanes W, Bronson P, Witebsky E: Precipitating antigens of the normal human prostate. J Reprod Fertil 1970, 22:573 -574. DOI: 10.1530/jrf.0.0220573
3. Chodak G, Schoenberg H: Early detection of prostate cancer by routine screening. JAMA 1984, 252:3261 -3264. DOI: 10.1001/jama.252.23.3261
4. Thompson I, Ernst J, Gangai M, Spence C: Adenocarcinoma of the prostate: results of routine urological screening. J Urol 1984, 132:690 -692.
5. Stamey T, Yang N, Hay A, et al.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987, 317:909 -916. This is a landmark paper that contributed to launching the “PSA era” for prostate cancer. DOI: 10.1056/NEJM198710083171501
6. Stamey T: The era of serum prostate-specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA. BJU Int 2004, 94:963 -964. DOI: 10.1111/j.1464-410X.2004.05212.x
7. Stamey T, Caldwell M, McNeal J, et al.: The prostate-specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years? J Urol 2004, 172:1297 -1301. DOI: 10.1097/01.ju.0000139993.51181.5d
8. Thompson I, Pauler D, Goodman P, et al.: Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004, 350:2239 -2246. DOI: 10.1056/NEJMoa031918
9. Hernandez J, Thompson I: Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 2004, 101:894 -904. DOI: 10.1002/cncr.20480
10. Chu K, Tarone R, Freeman H: Trends in prostate cancer mortality among black men and white men in the United States. Cancer 2003, 97:1507 -1516. This is one of the first publications suggesting that increased screening for prostate cancer may explain the recent decrease in mortality rates. DOI: 10.1002/cncr.11212
11. Partin A, Yoo J, Carter H, et al.: The use of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993, 150:110 -114.
12. Kattan M, Eastham J, Stapleton A, et al.: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998, 90:766 -771. DOI: 10.1093/jnci/90.10.766
13. D’Amico A: Combined-modality staging for localized adenocarcinoma of the prostate. Oncology (Huntingt) 2001, 15:1049 -1059; discussion 60 -62, 64 -65, 69 -70, 73 -75.
14. Wagner P, Verma M, Srivastava S: Challenges for biomarkers in cancer detection. Ann N Y Acad Sci 2004, 1022:9 -16. DOI: 10.1196/annals.1318.003
15. Killian C, Chu T: Prostate-specific antigen: questions often asked. Cancer Invest 1990, 8:27 -37.
16. Seamonds B, Yang N, Anderson K, et al.: Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers. Urology 1986, 28:472 -479. DOI: 10.1016/0090-4295(86)90146-9
17. Catalona W, Smith D, Ornstein D: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA 1997, 277:1452–1455. DOI: 10.1001/jama.277.18.1452
18. Gretzer M, Partin A: PSA markers in prostate cancer detection. Urol Clin North Am 2003, 30:677 -686. DOI: 10.1016/S0094-0143(03)00057-0
19. Catalona W, Bartsch G, Rittenhouse H, et al.: Serum pro prostate-specific antigen improves cancer detection compared to free and complexed prostate-specific antigen in men with prostate specific antigen 2 to 4 ng/mL. J Urol 2003, 170:2181 -2185. DOI: 10.1097/01.ju.0000095460.12999.43
20. Catalona W, Bartsch G, Rittenhouse H, et al.: Serum pro-prostate-specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/mL prostate-specific antigen. J Urol 2004, 171:2239 -2244. DOI: 10.1097/01.ju.0000127737.94221.3e
21. Carter H, Pearson J, Metter E, et al.: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992, 267:2215 -2220. DOI: 10.1001/jama.267.16.2215
22. Goluboff E, Heitjan D, De VG, et al.: Pretreatment prostatespecific antigen doubling times: use in patients before radical prostatectomy. J Urol 1997, 158:1876 -1878;discussion 8–9. DOI: 10.1016/S0022-5347(01)64154-5
23. Egawa S, Arai Y, Tobisu K, et al.: Use of pretreatment prostatespecific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis 2000, 3:269 -274. DOI: 10.1038/sj.pcan.4500424
24. Albertsen P, Hanley J, Penson D, Fine J: Validation of increasing prostate-specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol 2004, 171:2221 -2225. DOI: 10.1097/01.ju.0000124381.93689.b4
25. Pound C, Partin A, Eisenberger M, et al.: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281:1591 -1597. DOI: 10.1001/jama.281.17.1591
26. D’Amico A, Chen M, Roehl K, Catalona W: Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004, 351:125 -135. DOI: 10.1056/NEJMoa032975
27. Brawn P, Johnson E, Kuhl D, et al.: Stage at presentation and survival of white and black patients with prostate carcinoma. Cancer 1993, 71:2569 -2573. DOI: 10.1002/1097-0142(19930415)71:8<2569::AID-CNCR2820710822>3.0.CO;2-R
28. Hoffman R, Gilliland F, Eley J, et al.: Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2001, 93:388 -395. DOI: 10.1093/jnci/93.5.388
29. Thompson I, Tangen C, Tolcher A, et al.: Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst 2001, 93:219 -225. DOI: 10.1093/jnci/93.3.219
30. Powell I: Prostate cancer in the African American: Is this a different disease? Semin Urol Oncol 1998, 16:221 -226.
31. Stanford J, Ostrander E: Familial prostate cancer. Epidemiol Rev 2001, 23:19 -23.
32. Lichtenstein P, Holm N, Verkasalo P, et al.: Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000, 343:78 -85. DOI: 10.1056/NEJM200007133430201
33. Gonzalgo M, Isaacs W: Molecular pathways to prostate cancer. J Urol 2003, 170:2444 -2452. DOI: 10.1097/01.ju.0000085381.20139.b6
34. Balic I, Graham S, Troyer D, et al.: Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. J Urol 2002, 168:2245 -2248. DOI: 10.1016/S0022-5347(05)64364-9
35. Hsing A, Gao Y, Wu G, et al.: Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res 2000, 60:5111 -5116.
36. Nam R, Elhaji Y, Krahn M, et al.: Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. J Urol 2000, 164:567 -572. DOI: 10.1016/S0022-5347(05)67424-1
37. Giovannucci E, Stampfer M, Krithivas K, et al.: The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 1997, 94:3320 -3323. DOI: 10.1073/pnas.94.7.3320
38. Modugno F, Weissfeld J, Trump D, et al.: Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res 2001, 7:3092 -3096.
39. Hsing A, Chokkalingam A, Gao Y, et al.: Polymorphic CAG/ CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2002, 11:337 -341.
40. Ingles S, Ross R, Yu M, et al.: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997, 89:166 -170. DOI: 10.1093/jnci/89.2.166
41. Dejager S, Bry-Gauillard H, Bruckert E, et al.: A comprehensive endocrine description of Kennedy’s disease revealing androgen insensitivity linked to CAG repeat length. J Clin Endocrinol Metab 2002, 87:3893 -3901. DOI: 10.1210/jc.87.8.3893
42. Gsur A, Bernhofer G, Hinteregger S, et al.: A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer 2000, 87:434 -437. DOI: 10.1002/1097-0215(20000801)87:3<434::AID-IJC19>3.0.CO;2-G
43. Haiman C, Stampfer M, Giovannucci E, et al.: The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol Biomarkers Prev 2001, 10:743 -748.
44. Kittles R, Panguluri R, Chen W, et al.: Cyp17 promoter variant associated with prostate cancer aggressiveness in African Americans. Cancer Epidemiol Biomarkers Prev 2001, 10:943 -947.
45. Lunn R, Bell D, Mohler J, Taylor J: Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999, 20:1727 -1731. DOI: 10.1093/carcin/20.9.1727
46. Yamada Y, Watanabe M, Murata M, et al.: Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5 alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int J Cancer 2001, 92:683 -686. DOI: 10.1002/1097-0215(20010601)92:5<683::AID-IJC1255>3.0.CO;2-4
47. Thompson IM, Goodman PJ, Tangen CM, et al.: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215 -224. This is the only randomized clinical trial that has demonstrated the ability to prevent prostate cancer. DOI: 10.1056/NEJMoa030660
48. Makridakis N, diSalle SE, Reichardt J: Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II. Pharmacogenetics 2000, 10:407 -413. DOI: 10.1097/00008571-200007000-00004
49. Makridakis N, Ross R, Pike M, et al.: A prevalent missense substitution that modulates activity of prostatic steroid 5 alpha-reductase. Cancer Res 1997, 57:1020 -1022.
50. Nam R, Toi A, Vesprini D, et al.: V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence, and progression. Urology 2001, 57:199 -204. DOI: 10.1016/S0090-4295(00)00928-6
51. Makridakis N, Ross R, Pike M, et al.: Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 1999, 354:975 -978. DOI: 10.1016/S0140-6736(98)11282-5
52. Rebbeck T, Jaffe J, Walker A, et al.: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998, 90:1225 -1229. DOI: 10.1093/jnci/90.16.1225
53. Walker A, Jaffe J, Gunasegaram S, et al.: Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Hum Mutat 1998, 12:289.
54. Ingles S, Coetzee G, Ross R, et al.: Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res 1998, 58:1620 -1623.
55. Kibel A, Isaacs S, Isaacs W, Bova G: Vitamin D receptor polymorphisms and lethal prostate cancer. J Urol 1998, 160:1405 -1409. DOI: 10.1016/S0022-5347(01)62550-3
56. Beer T, Evans A, Hough K, et al.: Polymorphisms of GSTP1 and related genes and prostate cancer risk. Prostate Cancer Prostatic Dis 2002, 5:22 -27. DOI: 10.1038/sj.pcan.4500549
57. Rubin M, Zhou M, Dhanasekaran S, et al.: alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002, 287:1662 -1670. DOI: 10.1001/jama.287.13.1662
58. Jiang Z, Woda B: Diagnostic utility of alpha-methylacyl CoA racemase (P504S) on prostate needle biopsy [In Process Citation]. Adv Anat Pathol 2004, 11:316 -321. DOI: 10.1097/01.pap.0000146924.14246.be
59. Jiang Z, Woda B, Wu C, Yang X: Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S). Am J Clin Pathol 2004, 122:275 -289. DOI: 10.1309/EJUY-UQPE-X1MG-68MK
60. Rogers C, Yan G, Zha S, et al.: Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein. J Urol 2004, 172:1501 -1503. DOI: 10.1097/01.ju.0000137659.53129.14
61. Ross J, Sheehan C, Dolen E, Kallakury B: Morphologic and molecular prognostic markers in prostate cancer. Adv Anat Pathol 2002, 9:115 -128. DOI: 10.1097/00125480-200203000-00003
62. Pollack A, DeSilvio SM, Khor L, et al.: Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol 2004, 22:2133 -2140. DOI: 10.1200/JCO.2004.09.150
63. Li R, Heydon K, Hammond M, et al.: Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res 2004, 10:4118 -4124. DOI: 10.1158/1078-0432.CCR-1052-03
64. Pollack A, Grignon D, Heydon K, et al.: Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610. J Clin Oncol 2003, 21:1238 -1248. DOI: 10.1200/JCO.2003.02.025
65. Shariat S, Andrews B, Kattan M, et al.: Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001, 58:1008 -1015. DOI: 10.1016/S0090-4295(01)01405-4
66. Adler H, McCurdy M, Kattan M, et al.: Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999, 161:182 -187. DOI: 10.1016/S0022-5347(01)62092-5
67. Shariat S, Kattan M, Traxel E, et al.: Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 2004, 10:1992 -1999. DOI: 10.1158/1078-0432.CCR-0768-03
68. Amanatullah D, Reutens A, Zafonte B, et al.: Cell-cycle dysregulation and the molecular mechanisms of prostate cancer. Front Biosci 2000, 5:D372 -D390. DOI: 10.2741/Amanatullah
69. Ekici S, Cerwinka W, Duncan R, et al.: Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. Int J Cancer 2004, 112:121 -129. DOI: 10.1002/ijc.20368
70. Sedelaar J, van Leenders GJ, Hulsbergen-van de Kaa CA, et al.: Microvessel density: correlation between contrast ultrasonography and histology of prostate cancer. Eur Urol 2001, 40:285 -293. DOI: 10.1159/000049788
71. Leach F: Microsatellite instability and prostate cancer: clinical and pathological implications. Curr Opin Urol 2002, 12:407 -411. DOI: 10.1097/00042307-200209000-00007
72. Mouraviev V, Li L, Tahir S, et al.: The role of caveolin-1 in androgen-insensitive prostate cancer. J Urol 2002, 168:1589 -1596. DOI: 10.1016/S0022-5347(05)64526-0
73. Verma M, Wright G, Hanash S, et al.: Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers. Ann N Y Acad Sci 2001, 945:103 -115. DOI: 10.1111/j.1749-6632.2001.tb03870.x
74. Zheng Y, Xu Y, Ye B, et al.: Prostate carcinoma tissue proteomics for biomarker discovery. Cancer 2003, 98:2576 -2582. DOI: 10.1002/cncr.11849
75. Cazares L, Adam B, Ward M, et al.: Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res 2002, 8:2541 -2552.
76. Qu Y, Adam B, Yasui Y, et al.: Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002, 48:1835 -1843.
77. Zhukov T, Johanson R, Cantor A, et al.: Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer 2003, 40:267 -279.
78. Li J, Zhang Z, Rosenzweig J, et al.: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002, 48:1296 -1304.
79. Ardekani A, Liotta L, Petricoin E: Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev Mol Diagn 2002, 2:312 -320. DOI: 10.1586/14737159.2.4.312
80. Ball G, Mian S, Holding F, et al.: An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers. Bioinformatics 2002, 18:395 -404. DOI: 10.1093/bioinformatics/18.3.395
81. Zhang Y, Wu D, Guan M, et al.: Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient [In Process Citation]. Clin Biochem 2004, 37:772 -779. DOI: 10.1016/j.clinbiochem.2004.04.002
82. Grizzle W, Semmes O, Basler J, et al.: The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: a study in biomarker validation in genitourinary oncology. Urol Oncol 2004, 22:337 -343.
83. Banez L, Prasanna P, Sun L, et al.: Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 2003, 170:442 -446. DOI: 10.1097/01.ju.0000069431.95404.56
84. de Koning H, Auvinen A, Berenguer SA, et al.: Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary Cancer Trial. Int J Cancer 2002, 97:237 -244. DOI: 10.1002/ijc.1588
85. Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10 -30. DOI: 10.3322/canjclin.55.1.10
86. Smith R, Cokkinides V, Eyre H: American cancer society guidelines for the early detection of cancer, 2005. CA Cancer J Clin 2005, 55:31 -44.